Novo Nordisk gets a fresh $73.50 target as Amazon starts selling the Wegovy pill
CICC started coverage of Novo Nordisk’s U.S. ADR with an outperform rating and a $73.50 price target, about 28% above Thursday’s $57.34 close. Amazon Pharmacy began selling Novo’s Wegovy weight-loss pill, offering both insurance and cash-pay options. Novo’s ADR rose 1.36% Thursday, outperforming the S&P 500. The FDA approved the Wegovy pill in December.